FDA Says Mevacor OTC Label Needs “Major Revisions”
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency review finds only 1% of respondents in a label comprehension study correctly said they could use lovastatin 20 mg “right away.” OTC Division’s Ganley cites concerns in a letter to the Nonprescription Drugs and Endocrinologic & Metabolic Drugs advisory committees, which will review J&J/Merck’s Rx-to-OTC switch application.